Metraipolis › archive › dc_da8863ddfadb

Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice — Europe PMC PMID:41692425

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41692425
DOI
10.1002/cam4.71640
License (as archived)
solo-consultazione
Archived
2026-11-06T09:08:14.544Z
SHA-256 of the archived text
bf1e3cae8f682602c0997a08b88c8fbd4e6c0dd7fab5513ede3a68a156fd5e73
Stable URL of this page
https://metraipolis.com/documento/dc_da8863ddfadb

How to cite

Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice — Europe PMC PMID:41692425 — Europe PMC (en), https://europepmc.org/article/MED/41692425 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da8863ddfadb (Metraipolis archive dc_da8863ddfadb, sha256 bf1e3cae8f682602c0997a08b88c8fbd4e6c0dd7fab5513ede3a68a156fd5e73)
BibTeX
@misc{dcda8863ddfadb,
  title = {Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice — Europe PMC PMID:41692425},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41692425},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da8863ddfadb; sha256 bf1e3cae8f682602c0997a08b88c8fbd4e6c0dd7fab5513ede3a68a156fd5e73},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41692425. Agents can read the archived copy with the MCP tool read_document.